PALBOCICLIB

Brand name:

• Ibrance®

Pharmaceutical company:

Pfizer Australia Pty Ltd

Condition/indication:
(therapeutic use)

• Hormone receptor-positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) advanced or metastatic breast cancer

PBAC Submission type:

Change to listing (Category 3-4)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents – July 2021

Related medicines:

--

Submission received for:

July 2021 PBAC meeting

Opportunity for consumer comment:

Open 21/03/2021 and close 26/05/2021 (see PBS Website)

PBAC meeting:

Held on 07/07/2021

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

23/09/2021

Lodgement of required documentation:

07/10/2021

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 18/10/2021

Status:

Finalised

Government processes:

Commenced on 25/10/2021

Medicine listed on the PBS:

01/01/2022 (see PBS schedule)

---